Results 221 to 230 of about 108,288 (261)
Recurrent Extranodal Diffuse Large B-Cell Lymphoma Manifesting as a Cecal Mass Over 10 Years After Remission. [PDF]
ACG Case Rep JYadav J +5 more
europepmc +1 more source
Renal Diffuse Large B-cell Lymphoma Mimicking Acute Pyelonephritis on 18 F-FDG PET/CT. [PDF]
Clin Nucl MedWang W, Yan X, Yang S, Su X, Wang P.
europepmc +1 more source
Purpuric targetoid eruption revealing disseminated mucormycosis
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Francisco Mano, João Teixeira
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Critical Reviews in Oncology/Hematology, 2013
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Countries. Following, morphological, biological and clinical studies have allowed the subdivision of DLBCLs into morphological variants, molecular and immunophenotypic subgroups and distinct disease entities.
MARTELLI, Maurizio +5 more
openaire +2 more sources
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Countries. Following, morphological, biological and clinical studies have allowed the subdivision of DLBCLs into morphological variants, molecular and immunophenotypic subgroups and distinct disease entities.
MARTELLI, Maurizio +5 more
openaire +2 more sources
Pathology, 2018
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. Patients most often present with a rapidly growing tumour mass in single or multiple, nodal or extranodal sites.
Shaoying, Li +2 more
openaire +2 more sources
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. Patients most often present with a rapidly growing tumour mass in single or multiple, nodal or extranodal sites.
Shaoying, Li +2 more
openaire +2 more sources
Everolimus in Diffuse Large B-Cell Lymphomas
Future Oncology, 2015Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly activated pathway in DLBCL. Preclinical studies in DLBCL cell lines demonstrated that everolimus, an oral selective mTOR inhibitor, induces cell ...
Merli, Michele +4 more
openaire +4 more sources
Diffuse Large B-Cell Lymphomas and Burkitt Lymphoma
Hematology/Oncology Clinics of North America, 2009Diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphoma (BL) account for the majority of aggressive lymphomas in adults and children. DLBCLs exhibit marked biological heterogeneity and variable clinical presentation and clinical course. Conversely, BL is genetically relatively homogeneous but associated with variable clinicopathological features ...
Laurence, de Leval +1 more
openaire +2 more sources
Seminars in Radiation Oncology, 2007
Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients with different treatment outcome can be identified based on clinical and molecular prognostic factors.
openaire +2 more sources
Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients with different treatment outcome can be identified based on clinical and molecular prognostic factors.
openaire +2 more sources